Nexus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NEXUS, and what generic alternatives to NEXUS drugs are available?
NEXUS has twenty approved drugs.
There are five US patents protecting NEXUS drugs. There is one tentative approval on NEXUS drugs.
There are ten patent family members on NEXUS drugs in nine countries and eighty-eight supplementary protection certificates in nine countries.
Summary for Nexus
| International Patents: | 10 |
| US Patents: | 5 |
| Tradenames: | 22 |
| Ingredients: | 19 |
| NDAs: | 20 |
Drugs and US Patents for Nexus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexus | PROCAINAMIDE HYDROCHLORIDE | procainamide hydrochloride | INJECTABLE;INJECTION | 206332-001 | Oct 13, 2017 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Nexus Pharms | POTASSIUM CHLORIDE | potassium chloride | INJECTABLE;INJECTION | 217704-001 | Aug 14, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Nexus | STERILE WATER FOR INJECTION | sterile water for injection | LIQUID;N/A | 217536-001 | Jul 11, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Nexus | POTASSIUM CHLORIDE 10MEQ | potassium chloride | INJECTABLE;INJECTION | 214727-001 | Mar 18, 2021 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Nexus | LEVETIRACETAM IN SODIUM CHLORIDE | levetiracetam | INJECTABLE;INTRAVENOUS | 213532-003 | Jul 6, 2020 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nexus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2022532657 | ⤷ Try a Trial |
| South Korea | 20220009985 | ⤷ Try a Trial |
| Mexico | 2021013888 | ⤷ Try a Trial |
| Australia | 2020276619 | ⤷ Try a Trial |
| Japan | 2023091072 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Nexus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0253310 | SPC/GB95/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215 |
| 0478363 | 48/1999 | Austria | ⤷ Try a Trial | PRODUCT NAME: TIROFIBAN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: 1-23140 UND 1-23141 19990714; FIRST REGISTRATION: LI IKS-NR 54761 19980528 |
| 1713823 | 92595 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516 |
| 2822954 | 1890030-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625 |
| 2822954 | LUC00083 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
